Skip to Content

Andrew Wei

Professor Wei has a current appointment in the acute leukaemia and myelodysplastic tumor stream at the Peter MacCallum Cancer Centre & Royal Melbourne Hospital. As a clinical haematologist, Professor Andrew Wei has played an active role in the development of venetoclax and oral azacitidine for patients with AML. He has been the AML working party chairperson for the Australasian Leukaemia and Lymphoma Group (ALLG) since 2009, developing and mentoring new fellows to conduct nationwide clinical trials in AML. Professor Wei also heads a laboratory in the Division of Blood Cells and Blood Cancer at the Walter and Eliza Hall Institute of Medical Research, where his lab has a focus on novel drugs and combinations targeting pro-survival pathways in AML.

Back to top